Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma

Ixazomib is the first oral proteasome inhibitor to enter the clinic. Given the efficacy of bortezomib in combination with cyclophosphamide and dexamethasone, we studied the combination of ixazomib, cyclophosphamide and dexamethasone (ICd) in newly diagnosed multiple myeloma (NDMM) and patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumar, Shaji K., Buadi, Francis K., LaPlant, Betsy, Halvorson, Alese, Leung, Nelson, Kapoor, Prashant, Dingli, David, Gertz, Morie A., Go, Ronald S., Bergsagel, P. Leif, Lin, Yi, Dispenzieri, Angela, Hwa, Yi Lisa, Fonder, Amie, Hobbs, Miriam, Fonseca, Rafael, Hayman, Suzanne R., Stewart, A. Keith, Lust, John A., Mikhael, Joseph, Gonsalves, Wilson, Reeder, Craig, Skacel, Tomas, Rajkumar, S. Vincent, Lacy, Martha Q.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6066484/
https://www.ncbi.nlm.nih.gov/pubmed/30061664
http://dx.doi.org/10.1038/s41408-018-0106-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6066484/
https://www.ncbi.nlm.nih.gov/pubmed/30061664
http://dx.doi.org/10.1038/s41408-018-0106-3

Ejemplares similares